BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
The purpose of this study is to study two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects.
This is a prospective, 4 arm, multicenter, randomized, Phase II study in subjects with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects. This study will evaluate the use of two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects. The primary objective is to evaluate the objective PFS of abiraterone/prednisone, olaparib or the combination abiraterone/prednisone + olaparib in mCRPC patients with canonical DNA repair defects in BRCA1,BRCA2, or ATM.
Participants will not be paid for their participation.
- IRB Number: 1708862929 (C16-168)
- Research Study Identifier: TX8334
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required